<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51995">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01948830</url>
  </required_header>
  <id_info>
    <org_study_id>CRFB002A2411</org_study_id>
    <secondary_id>2013-002626-23</secondary_id>
    <nct_id>NCT01948830</nct_id>
  </id_info>
  <brief_title>Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD</brief_title>
  <acronym>TREND</acronym>
  <official_title>A 12-month, Phase IIIb, Randomized, Visual Acuity Assessor-masked, Multicenter Study Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen Compared to Monthly Regimen, in Patients With Neovascular AMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <authority>Spain: Ministry of Health</authority>
    <authority>Argentina: Ministry of Health</authority>
    <authority>Brazil: Ministry of Health</authority>
    <authority>Colombia: National Institutes of Health</authority>
    <authority>Croatia: Ministry of Health and Social Care</authority>
    <authority>Denmark: The Ministry of the Interior and Health</authority>
    <authority>Egypt: Ministry of Health and Population</authority>
    <authority>Finland: Ministry of Social Affairs and Health</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Guatemala: Ministry of Public Health and Social Assistance</authority>
    <authority>Hungary: Research Ethics Medical Committee</authority>
    <authority>India: Ministry of Health</authority>
    <authority>Ireland: Ministry of Health</authority>
    <authority>Solomon Islands: National Health Research Ethics Committee</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Korea: Food and Drug Administration</authority>
    <authority>Latvia: State Agency of Medicines</authority>
    <authority>Mexico: Ministry of Health</authority>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <authority>Netherlands: Ministry of Health, Welfare and Sport</authority>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <authority>Poland: Ministry of Health</authority>
    <authority>Portugal: National Pharmacy and Medicines Institute</authority>
    <authority>Romania: National Authority for Scientific Research</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Serbia and Montenegro: Agency for Drugs and Medicinal Devices</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>Slovenia: Ministry of Health</authority>
    <authority>South Africa: Department of Health</authority>
    <authority>Sweden: The National Board of Health and Welfare</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and safety of two different regimens of 0.5
      mg ranibizumab given as intravitreal injection in patients with neovascular age-related
      macular degeneration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 12-month, phase IIIb, randomized, Visual Acuity assessor-masked, multi-center,
      interventional study assessing the efficacy and safety of the TER vs monthly regimens of 0.5
      mg ranibizumab intravitreal (IVT) injections in patients with newly diagnosed nAMD.
      Patients will be randomized 1:1 into one of two treatment arms, Treat and Extend or monthly
      regimens.

      There will be 3 periods in this study: Screening period (up to 14days), treatment period (11
      months), follow-up period (1 month). At randomization visit patients will be randomized into
      one of the 2 treatment groups Group I ranibizumab 0.5 mg based on monthly treatment or Group
      II ranibizumab 0.5 mg based on TER (randomization ratio of 1:1) and will receive the first
      dose of Investigational treatment. Patients in Group I the following visits will perform on
      monthly intervals. For patients in Group II the investigator will evaluate disease activity
      (i.e., signs of exudation) based on SD-OCT, and in case of absence of disease activity every
      next visit will be 2 weeks), with a maximum of a 12-week interval.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>BCVA change; by measuring BCVA score at 4 meters distance using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To demonstrate that the ranibizumab Treat and Extend regimen is non-inferior to ranibizumab monthly regimen in patients with nAMD as assessed by the change in best corrected visual acuity (BCVA) from baseline to Month 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in BCVA score from baseline to month 12</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the change in BCVA from baseline over time up to Month 12 by measuring BCVA score at 4 meters distance using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits scheduled</measure>
    <time_frame>From Month1 to Month 11</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of visits scheduled according to the treat and extend regimen after treatment initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Best Corrected Visual Acuity (BCVA) improvements ≥1, ≥5, ≥10, ≥15, and ≥30 letters by visit</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the occurrence of BCVA improvements of ≥1, ≥5, ≥10, ≥15, and ≥30 letters from baseline, over time up to Month 12. Measurements taken at 4 meters distance using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Best Corrected Visual Acuity (BCVA) loss &gt;=73 letters by visit</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the occurrence of absolute BCVA ≥73 letters (20/40 Snellen equivalent) over time up to Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Best Corrected Visual Acuity (BCVA) loss &lt;5, &lt;10, and &lt;15 letters by visit</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the occurrence of BCVA losses of &lt;5, &lt;10 and &lt;15 letters from baseline, over time up to Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCVA score measured at 4 meters distance using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the time course of mean BCVA from baseline up to Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average change in BCVA from Baseliine to Month 12</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>BCVA score measured at 4 meters distance using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period (time) between injections</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess treatment frequency and average dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of the disease activity</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the occurrence of a fluid free macula (e.g., no intra-retinal and/or sub-retinal fluid as measured on spectral domain OCT (SD-OCT) over time up to Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in central retinal thickness of the study eye over time</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the change in central subfield retinal thickness (CSFT) collected by SD-OCT, as evaluated by the Central Reading Center (CRC) from baseline, over time up to Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Choroidal Neovascularization (CNV) leakage in the study eye</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate presence of active CNV leakage on fluorescein angiography (FA) by reading center over time up to Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the impact on patient functioning and quality of life supported by ranibizumab 0.5 as assessed by the NEI-VFQ-25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events as a measure of Safety and Tolerability</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">644</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <condition>Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monthly regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treat and Extend regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 0.5mg</intervention_name>
    <description>0.5 mg ranibizumab (intravitreal injections)</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 0.5mg</intervention_name>
    <description>0.5 mg ranibizumab (intravitreal injections)</description>
    <arm_group_label>Group II</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, ≥50 years of age with signed informed consent before study
             procedures

          -  Visual impairment predominantly due to nAMD.

          -  Active CNV secondary to AMD confirmed by presence of active leakage from CNV seen by
             fluorescein angiography (FA) and/or color fundus photography

          -  Presence of intra- or subretinal fluid/hemorrhage seen by SD-OCT

          -  BCVA score must be ≤ 78 and ≥ 23 letters at 4 meters starting distance using Early
             Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity charts (approximate
             Snellen equivalent of 20/32 and 20/320)

        Exclusion Criteria:

          -  Any type of advanced, severe or unstable disease, including any medical condition
             (controlled or uncontrolled) that could be expected to progress, recur, or change to
             such an extent that it may bias the assessment of the clinical status of the patient
             to a significant degree or put the patient at special risk.

          -  Stroke or myocardial infarction within 3 months prior to Screening.

          -  Any active periocular or ocular infection or inflammation in both eyes.

          -  Ocular disorders in the study eye at the time of enrollment that may confound
             interpretation of study results and compromise visual acuity.

          -  Presence of amblyopia or amaurosis in the fellow eye.

          -  History of treatment with any anti-angiogenic drugs (including any anti- vascular
             endothelial growth factor (anti-VEGF) agents) e.g., bevacizumab [Avastin®],
             aflibercept [Eylea®]) or vPDT in the study eye.

          -  History of intravitreal treatment with corticosteroids within 6 months and history of
             intra-ocular surgery within 3 months in the study eye prior to the Screening.

          -  Pregnant or nursing (lactating) women. Women of child-bearing potential, defined as
             all women physiologically capable of becoming pregnant, unless they are using
             effective methods of contraception during dosing of study treatment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottignies</city>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zottegem</city>
        <zip>9620</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roskilde</city>
        <zip>DK-4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cairo</city>
        <state>Abbassia</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chemnitz</city>
        <zip>09116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Darmstadt</city>
        <zip>64298</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siegburg</city>
        <zip>53721</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sulzbach</city>
        <zip>66280</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1133</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560010</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sassari</city>
        <state>SS</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-354</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3030-163</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1150</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xira</city>
        <zip>2600-009</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97517</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>82606</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nove Zamky</city>
        <zip>94001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poprad</city>
        <zip>05845</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zilina</city>
        <zip>01207</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valladolid</city>
        <state>Castilla y Leon</state>
        <zip>47011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sant Cugat</city>
        <state>Cataluña</state>
        <zip>08190</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Binningen</city>
        <zip>4102</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06490</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34420</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 22, 2014</lastchanged_date>
  <firstreceived_date>September 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ranibizumab, Lucentis, choroidal neovascularization, age-related macular degeneration, treat and extend regimen</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
